Top Markets
Coin of the day
Caliway Biopharmaceuticals Co. L Caliway Biopharmaceuticals Co. L

Caliway Biopharmaceuticals Co. L

6919
주식 순위 #3556
Caliway Biopharmaceuticals Co., Ltd., and its affiliated entities, is dedicated... Caliway Biopharmaceuticals Co., Ltd., and its affiliated entities, is dedicated to developing pharmaceuticals primarily in the fields of aesthetic medicine and chronic inflammation. Its lead investigational drug, CBL-514, is currently undergoing Phase 2 clinical trials, targeting non-surgical fat reduction, Dercum's disease, and cellulite. Beyond this, the firm is also progressing CBA-539 through preclinical exploration for potential applications in central obesity, hyperpigmentation, and skin aging. The company's offerings also extend to dietary supplements. Established in 2012, Caliway Biopharmaceuticals operates from its headquarters in New Taipei City, Taiwan.
주가
$3.28
마지막 동기화: 2026-07-31
시가총액
$5.10B
변동 (1일)
0.00%
변동 (1년)
-49.70%
국가
TW
거래 Caliway Biopharmaceuticals Co. L (6919)

카테고리

Caliway Biopharmaceuticals Co. L (6919)의 EPS
2026 기준 EPS TTM: 0
Caliway Biopharmaceuticals Co. L의 최신 재무 보고서와 주가에 따르면, 현재 EPS (TTM)는 0입니다. 2026년 말에는 회사의 EPS가 0였으며, 이는 2026년의 EPS 0와 동일입니다.
Caliway Biopharmaceuticals Co. L의 EPS 기록 (2026 ~ 2026)
매년 말의 EPS
연도 EPS 변화
제공된 날짜에 대한 데이터가 충분하지 않습니다.
유사 기업 또는 경쟁사의 EPS
회사 EPS EPS 차이 국가
$17.32 -
US
$27.74 -
NL
$-7.98 -
US
$-5.29 -
AU
- -
CH